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What is already known about this topic? 36 
 Prenatal WES generates variants of uncertain significance (VUS) and 37 
incidental findings (ICFs).  38 
What does this study add? 39 
 Consent-takers require training.  40 
 An overview of the findings that will/won’t be reported should be provided.  41 
 Patient Representative Groups (PRGs) felt women want access to all 42 
information and re-interpretation of results over time. 43 
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 Clinical Professionals (CPs) felt that interpretation should be at the point of 44 
testing only. 45 
 46 
Abstract 47 
Objective 48 
Focus groups were conducted with individuals involved in prenatal diagnosis to 49 
determine their opinions relating to WES in fetuses with structural anomalies.  50 
Method 51 
Five representatives of patient groups/charities (PRGs) and eight clinical 52 
professionals (CPs) participated.  Three focus groups occurred (the two groups 53 
separately and then combined).  Framework analysis was performed to elicit themes.  54 
A thematic coding frame was identified based on emerging themes.  55 
Results 56 
Seven main themes (consent, analysis, interpretation/reinterpretation of results, 57 
prenatal issues, uncertainty, incidental findings, and information access) with sub-58 
themes emerged.  The main themes were raised by both groups, apart from 59 
‘analysis’ which was raised by CPs only.  Some subthemes were raised by PRGs 60 
and CPs (with different perspectives).  Others were raised either by PRGs or CPs, 61 
showing differences in patient/clinician agendas. 62 
Conclusions 63 
Prenatal consent for WES is not a ‘perfect’ process but consent takers should be 64 
fully educated regarding the test.  PRGs highlighted issues involving access to 65 
results feeling that women want to know all information.  PRGs also felt that patients 66 
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want re-interpretation of results over time whilst CPs felt that interpretation should be 67 
performed at the point of testing only.  68 
Key words: Prenatal; genetic testing; whole exome sequencing. 69 
 70 
Introduction 71 
Standard chromosome testing (G-band karyotyping) undertaken prenatally has been 72 
largely superseded by the use of chromosomal microarrays (CMAs)1 identifying sub-73 
microscopic rearrangements undetectable by conventional cytogenetic methods2. 74 
Next generation sequencing (NGS) technologies represent a further development in 75 
terms of the quantity of genetic data obtainable and the bioinformatics needed to 76 
fully utilise and interpret results3.  NGS offers knowledge, but comes with 77 
challenges4.  Genome wide testing produces huge quantities of information, some of 78 
which may be uncertain and/or unanticipated, raising ethical concerns about 79 
disclosure and stimulating debate regarding how best to integrate such testing into 80 
prenatal clinical practice5.   81 
Within the postnatal/paediatric setting parents value being able to choose the types 82 
of genetic information they wish to receive and their understanding of the different 83 
options for the return of findings (and the implications of receiving different kinds of 84 
results) can be facilitated by the consent process6.  Parents do not express desire to 85 
know any and all genetic findings7, rather they prefer to receive information that they 86 
consider to be actionable, allowing them to balance the possible benefits and harms 87 
of learning their children’s genetic results8.  Parents can sometimes find themselves 88 
  5 
 
in uncharted territory needing to decide which types of findings (beyond primary 89 
variants) to receive7.     90 
There is little guidance relating to the process and content of informed consent for 91 
whole genome sequencing (WGS) and whole exome sequencing (WES) in the 92 
prenatal setting or the means by which results should be reported back to families9.  93 
Despite uncertainties, sequencing technologies are being introduced to clinical 94 
practice and reduction in cost is focusing the need to evaluate the balance of 95 
potential benefits and harms for patients undergoing prenatal genetic diagnosis10.  A 96 
significant barrier to the integration of WES/WGS into clinical care involves the 97 
management of incidental findings (results that are not related to the patient’s clinical 98 
indication for testing)9.  The issue is compounded by the biological time-frame of 99 
pregnancy, which creates a sense of time pressure11.  It is essential that we seek to 100 
understand the impact WGS/WES (and the uncertainty associated with it) has on 101 
families, if not we risk, potentially incorrectly, assuming families are making properly 102 
informed decisions12.   103 
As a first step to gain insight into the opinions of individuals with personal or 104 
professional experience of WES within the prenatal setting, focus group sessions 105 
were conducted with representatives of patient groups/charities (PRGs) that support 106 
families undergoing genetic testing and genetic diagnosis, and clinical professionals 107 
and clinical genetic scientists (CPs) involved in prenatal diagnosis to discuss the 108 
issues.  The aim of the focus group sessions with PRGs and CPs reported here was 109 
to gain information to subsequently inform ethical guidance relating to prenatal 110 
genetic sequencing and to help design an interview schedule to be used to 111 
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understand the experiences of families undergoing prenatal WES as a further phase 112 
of the work. 113 
 114 
Method 115 
To identify participants for the PRG and CP focus groups members of the Prenatal 116 
Assessment of Genomes and Exomes (PAGE) Study working group used 117 
convenience sampling13 to contact individuals known to be experts in their field.  118 
Three groups were held in succession during the afternoon of 9th October 2014. 119 
The first focus group consisted of five PRGs from the charities; Antenatal Results 120 
and Choices (ARC), Genetic Alliance UK, SWAN and Unique.  The second focus 121 
group consisted of eight CPs (two fetal medicine consultants, two genetic 122 
counsellors, two consultant clinical geneticists and two clinical genetic scientists).  123 
The third focus group combined all thirteen participants of the first and second focus 124 
groups.  The focus groups were conducted by SH, EQJ and MP using a topic guide; 125 
the main areas covered are shown in Table 1.  We held separate focus groups of 126 
PRGs and CPs first in order to allow for any topics to be discussed that might not be 127 
discussed in the presence of the other group.  The third group used the same topic 128 
guide, but focused on areas that had been felt by the facilitators to be areas of 129 
differences of opinion (between the CPs and PRGs) during focus groups one and 130 
two.  The size of the focus groups was limited by the number of professionals we 131 
could assimilate geographically on the same day.  All participants gave written 132 
consent.  Ethical approval for the focus groups was provided by the NRES 133 
Committee West Midlands –South Birmingham (14/WM/0150). 134 
 135 
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Analysis 136 
The focus groups were voice recorded and then transcribed verbatim.  Data was 137 
analysed using a thematic approach14,15.  To gain familiarization with the data the 138 
transcripts were read and re-read by SH and EQJ.  Throughout this process key 139 
ideas and recurrent themes were noted.  A coding frame was then identified based 140 
on the emerging themes.  The coding frame was refined as transcripts were added. 141 
This was agreed between three authors (SH, EQJ and SG).  All text was indexed 142 
numerically, with numbers placed in the margin beside the text.  The original pieces 143 
of data were charted using Excel (©Microsoft Office 2010).  Charts were developed 144 
using themes and subthemes.  145 
 146 
Results 147 
The thirteen participants came from four different charities and six healthcare sites 148 
within three geographical areas of the UK (Table 2).  Seven main themes with sub-149 
themes were identified.  With the exception of theme two, ‘Analysis’, which was 150 
raised by CPs only (FG1) all themes were discussed by both PRGs and CPs (FG1 151 
and FG2). Within those seven main themes some similar subthemes were either a) 152 
raised by both groups (with similar or different opinions) or b) different subthemes 153 
were raised by the separate groups, showing a difference in the patient and clinician 154 
agenda (Table 3).  Quotations with their focus group identifier (FG1, FG2, and FG3) 155 
are used to reflect the themes and sub-themes.  156 
Theme One: Consent  157 
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The first theme, consent, was discussed by PRGs and CPs.  Much of the discussion 158 
focused on the problem of consenting for a complicated test and the time/resources 159 
that facilitating informed consent would require.  In addition, the possibility of an ‘opt 160 
in’ consent form was discussed whereby patients could give different levels of 161 
consent depending on the results they wanted to receive.  162 
Both PRGs and CPs expressed concern about how much detailed information 163 
should be given in the consent process:  164 
CP “There seems to be a variation and divergence of opinion between clinical 165 
geneticists and the clinicians that deal with the parents as to how much information 166 
needs to be provided about problems that are clearly not related to the indication or 167 
reason for testing and I think that is my major concern” FG2 168 
Both expressed concern about who would obtain consent and the possibility of an 169 
‘education gap’ if those taking consent did not have a full understanding of the 170 
testing: 171 
PRG “Who is going to be doing all this counselling?  It can’t possibly be Geneticists, 172 
it’s going to be non-genetics professionals and I think there is a huge education gap 173 
there which needs filling” FG1 174 
Both also expressed concern about adding pressure to ‘overstretched services’ and 175 
the time it would take to consent for prenatal WES given the scope of what it could 176 
report:  177 
PRG “I think there is a worry too about the pressure it puts on genetics, pressure on 178 
genetic counsellors, because it is all, certainly in the first instance, going to be 179 
focused on them and they are already stretched” FG1 180 
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Finally both PRGs and CPs discussed the option of an ‘opt in’ consent form whereby 181 
patients could choose to receive findings of incidental significance in addition to 182 
results relating to the primary reason for testing.  PRGs felt this was something 183 
patients would welcome.  CPs however felt that this type of consent would need to 184 
be taken by a clinical geneticist or genetics counsellor. 185 
An area discussed by PRGs only was motivation for testing.  PRGs felt the most 186 
common motivation for testing was reassurance.  Other motivators were recurrence 187 
risk, ‘for extra information’ and wanting a genetically perfect baby: 188 
PRG “maybe there would be pressure for people to make sure their baby is 189 
perfect…it is a bit of a nightmare really” FG1 190 
Theme Two: Analysis  191 
This theme was only discussed by the CP group.  This is not surprising given that 192 
the CP group contained clinical scientists.  The potential to ‘target’ the testing to 193 
relevant genes was discussed.  It was felt this would negate the problem of 194 
incidental findings but in practice would be difficult to achieve given the current limits 195 
of genetic knowledge: 196 
CP “I kind of assume that you are going to do a target interpretation of that data and 197 
what you target is going to affect how you consent so if you are not going to look at 198 
BRCA1 and BRCA2 then you don’t need to consent about it” FG2 199 
Theme Three: Interpretation/reinterpretation of results   200 
Although this was discussed by both PRGs and CPs, there was a difference of 201 
opinion between the groups regarding reinterpretation of results over time.  CPs felt 202 
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results should be reviewed at the time of testing only.  PRGs felt that patients would 203 
want information as and whenever it became available:   204 
PRG “Our families that we support, they live without knowing for years and years, 205 
some of them, and their need for that diagnosis never goes away…if something five 206 
years down the line came up and suddenly they could link that then those families 207 
would most definitely want to know” FG3 208 
CP “it is a unique situation in medicine where we might have to reinterpret a test that 209 
was done for an entirely different reason five years ago in the context of what is 210 
known now…if the mother or father had not reported it [a medical concern] and the 211 
child hasn’t been presented to a medical practitioner, do we have a right to go along 212 
[contact the family] and say okay we found this relationship [genetic variation] exists 213 
and disrupt this family when they have perceived no medical problem at all?” FG3 214 
Only PRGs discussed access to the generated genetic data: 215 
PRG “a high percentage of families said if you had knowledge about me, my child or 216 
my baby, that is my knowledge and I want it, even to the point of wanting the raw 217 
sequencing data” FG1 218 
PRGs felt that women and their families wanted ‘all’ the information possible but that 219 
when the test became a reality fewer may choose to receive results of uncertain 220 
significance or incidental findings: 221 
PRG “Experience from when the Huntington’s test was made available on the NHS 222 
was that the community wanted it and everyone would go for it and then in practice I 223 
think it’s about a third go for it…we think maybe this (WES) is the same thing again” 224 
FG1 225 
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Theme Four: Issues specific to prenatal WES  226 
The reasons that prenatal exome sequencing is different from postnatal sequencing 227 
were explored by both PRGs and CPs.  Both agreed that pregnancy is a uniquely 228 
stressful situation with a ‘biological timeframe’: 229 
PRG “Your mind is jelly.  It takes you weeks to get your mind working properly, even 230 
if you are in the business, so God help people who have not even got the basic 231 
knowledge of what genetic testing is and what it means” FG1 232 
The PRGs alone discussed non-agreement between partners.  They also discussed 233 
the difficulties that couples have prenatally making an ‘imaginary leap’ as to what 234 
they would do with results: 235 
PRG “a lot of people they will nod their heads and make the right noises but they 236 
might not have thought the consequences through and they are the ones when 237 
something anomalous is picked up who will need the most time and concentration in 238 
helping them to work out what the result means to them” FG1 239 
The CPs group raised the issue that there is a more ambiguous phenotype 240 
antenatally, for instance you cannot see neurodevelopment, and this is an obvious 241 
limitation to counselling.  242 
Theme Five: Uncertainty 243 
There is often uncertainty in prenatal counselling for structural fetal anomalies as the 244 
full phenotype may not be detectable on scan and a genetic diagnosis maybe 245 
associated with variable penetrance.  Additionally WES detects variants where there 246 
is not enough definitive information to say that the genetic difference is the cause of 247 
  12 
 
the scan findings.  These variants of uncertain significance (VUS) present difficulties 248 
in the counselling of women if they are reported.   249 
Both the CPs and PRGs agreed that reporting VUS to patients can have a negative 250 
impact on the patient and potentially the doctor-patient relationship: 251 
CP “The time that I have had patients really angry has been when I have been 252 
reporting back uncertainty.  They are in the middle of this situation where they are 253 
trying to make a decision and I tell them something and then say “but I don’t know 254 
what that means” and I have had really angry reactions” FG2 255 
However both groups also agreed that VUS should not be withheld: 256 
PRG “there is a tremendous pressure when they (CPs) are giving information for 257 
which they can give no real certainty…but I would not want that to take away from 258 
the autonomy of that woman from making a decision to end the pregnancy if that is 259 
what they [she would] want because the potential we have at the moment is to 260 
potentially be paternalistic about the information given because of what might be 261 
done with it” FG1 262 
There was also consensus between the groups that VUS should be recorded in 263 
databases to build up a picture of whether the variants are benign or pathological.  264 
Theme Six: Incidental findings and prenatal WES 265 
WES is capable of detecting ‘incidental findings’ which are mutations which can 266 
sometimes associate with pathology.  These findings are incidental because they are 267 
unrelated to the reason for testing.  Reporting incidental findings will have 268 
implications for CPs’ time and healthcare resources, and there was a difference 269 
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between the views of CPs and PRGs.  Some CPs felt that incidental findings should 270 
not be reported: 271 
CP “We don’t have a national screening program [to identify incidental findings] (for 272 
adults) so why are we doing screening by subterfuge [to detect such findings] 273 
through the fetus” FG2 274 
Other CPs discussed that there appears to be a progression to the reporting of 275 
incidental findings postnatally if there is treatment for the condition available.  276 
PRGs highlighted the potential injury to the relationship between patients and 277 
medical professionals if an incidental result was revealed subsequently and it was 278 
felt this information had been withheld. 279 
Theme Seven: Access to prenatal WES information 280 
Both the PRGs and CPs agreed on the need for clear detailed written information to 281 
take away after the consultation.  The PRGs suggested more detailed signposting or 282 
information sharing, particularly in relation to patient charities that could provide 283 
focused support to families.  CPs also highlighted the need for national reporting 284 
guidance:  285 
CP “There should be some written information.  Ideally in this day and age and 286 
definitely in 10 years there should be a dedicated website that they (parents) can 287 
access and find out information” FG2 288 
CP “I think the ideal scenario would be to have national or even better international 289 
criteria for what is a definite [pathological variant] and what is a VUS and therefore 290 
you minimise the possibility [of uncertainty] for the parents” FG2 291 
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 292 
Conclusions 293 
All themes, with the exception of ‘Analysis’, were discussed by both CPs and PRGs.  294 
Both groups generally had similar opinions.  The process of consent for prenatal 295 
WES was considered and concerns were raised regarding the current lack of clinical 296 
geneticists/counsellors available to facilitate consent in prenatal clinical practice 297 
within the UK National Healthcare System.  298 
They also discussed the depth of the consent prior to the test, particularly when 299 
taken under stressful circumstances.  Previously authors have commented “that it is 300 
virtually impossible to counsel in these circumstances”16.  When pregnant women 301 
find themselves in a stressful position, they may cope by complying with what they 302 
believe is the health professional’s recommendations17.  It was generally agreed that 303 
clinicians should do the best job possible pre-test but understand that the process 304 
will not be perfect and that more detailed information should be provided to families 305 
when genetic anomalies are found. 306 
The issue of access to results was highlighted by the PRGs who felt that women 307 
would want to know all information generated as it was ‘their genome’.  PRGs also 308 
felt that patients would ideally want reinterpretation of genetic information over time, 309 
for instance if a VUS was recorded and was later found out to be pathological.  310 
Conversely some CPs felt that interpretation should be performed at the point of 311 
testing only and that on-going review was unsustainable.  This is in contrast to the 312 
views of Yu et al that propose “results should be viewed as a dynamic, sustained 313 
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resource of information that is available to an individual not only at a single point in 314 
time, but over many years and even possibly a lifetime”18.  315 
It was felt that conveying uncertain information could create tension in the doctor 316 
patient relationship.  In these circumstances patients require rapid follow up with a 317 
consultant clinical geneticist.  Even when this has occurred people may make 318 
incorrect conclusions to fit with their own schemata12.  Bernhardt et al interviewed 319 
women with VUS.  Many of them considered uncertainty to be information that they 320 
wished they did not have (“toxic knowledge”)2.  Women were left feeling anxious, 321 
and these concerns lingered into worries about their child’s development.  This 322 
would be in opposition to recent research showing that patients consider all 323 
information very important19.  324 
Some CPs felt that we should not report genes relating to adult onset conditions and 325 
allow the sequencing to become a screening test.  However there has been 326 
progression towards reporting of adult onset conditions in the postnatal arena (as per 327 
guidance by the ACMG20) and it seems possible that this may transfer into the 328 
prenatal setting.  Srebniak et al found that 55% of future parents want to be informed 329 
about adverse health effects at an adult stage but did not make a distinction between 330 
treatable and non treatable conditions21.  331 
The potential contrast in views of the CPs and PRGs is also highlighted in the recent 332 
publication of views of nearly 7000 people on the return of incidental results from 333 
genetic sequencing22.  Here compared with the public, genetic health professionals 334 
were five times more likely to think that incidental findings should not be returned. 335 
Participants were more interested in learning about conditions that were preventable 336 
and less interested in receiving information that is uncertain and cannot be 337 
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interpreted at the moment.  It maybe that genetic health professionals anticipate a 338 
vast increase in workload with the seemingly rapid progression towards the use of 339 
sequencing in the prenatal and postnatal setting22.  Recently Kalynchuk et al 340 
surveyed parental attitudes to WES and found that 83% felt it should be offered and 341 
54% would potentially accept it.  Only 2.2% were opposed to the testing.  However 342 
over 70% reported an increased risk of adult onset conditions or a variant of 343 
uncertain significance would cause them anxiety23.      344 
 345 
Limitations 346 
The number of focus group participants was limited by the number of CPs and PRGs 347 
who could be brought together geographically.  Therefore this is a relatively small 348 
study.  However it has been suggested that in qualitative work a small sample can 349 
provide useful information about participants’ experience 24. The number of focus 350 
groups we carried out accords with guidance for a ‘small’ study25, in which we were 351 
seeking information to inform further work and we did not aim or claim to reach data 352 
saturation26.  We cannot comment on the extent to which the views expressed reflect 353 
those of CPs and PRGs as a whole, and further themes such may have arisen had 354 
we carried out further focus groups.  There are a number of stakeholder groups 355 
involved in WES.  This paper has presented the views of two such groups and 356 
although the patients’ opinions themselves were not included in this study, we were 357 
able to gain useful insights into the topic area to inform further work to explore 358 
families’ experiences.  Using the themes which emerged from our focus groups a 359 
semi-structured interview has been designed and patients will be interviewed to 360 
determine their opinions on prenatal exome sequencing as part of the PAGE project 361 
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(http://www.pageuk.org).  The opinions of obstetricians and gynaecologists, who are 362 
not specialists in fetal medicine, were not explored in this research and the 363 
perspectives of this particular group of clinical professionals may well have revealed 364 
some additional insights.  There may also be details of significance that participants 365 
might have been willing to share more privately rather than in a focus group setting 366 
27.  As private feedback was not sought from participants following the focus groups 367 
we are unable to comment on this, and as such the authors accept this as limiting 368 
aspect of this research.    369 
It is premature to make concrete recommendations from these qualitative data but 370 
our findings suggest that consent in the prenatal arena is not a ‘perfect’ process. 371 
Consent-takers should be fully educated regarding the test. This work did not seek to 372 
fully explore the characterisation of the information that should be conveyed to make 373 
consent valid.  We feel that further qualitative work needs to explore this and in 374 
particular capture the views of women and their families.   375 
 376 
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